McLaren Flint Michigan State University, Flint, MI
Basel Abdelazeem , Kirellos Said Abbas , Fatma Labieb , Abdul Karim Arida , Nahla Ahmed El-Shahat , Joseph Shehata , Emad Kandah , Bilal Malik , Maxwell Oluwole Akanbi , Abdul Rafae , Nayha Tahir , Ahsan Wahab , Hamid Ehsan
Background: There is an emerging role of immunotherapy plus chemotherapy (ICC) in the front-line setting for the treatment of Non-Small Cell Lung Cancer (NSCLC) with reported improvement in overall survival (OS) and progression-free survival (PFS). In this review, we highlighted the efficacy and safety of combination regimens as a first-line therapy for NSCLC. Methods: A comprehensive literature search was done on PubMed, Cochrane, Embase, WOS, and Scopus until Dec-2021. The outcomes included progression free survival (PFS) and/or overall survival (OS) and treatment-related adverse events (TRAEs). The inverse variance method was used to generate hazard ratios (HR) with the corresponding 95% confidence intervals for the OS and PFS. Meanwhile, Mantle-Hazard variance was used to create risk ratios for TRAEs. Results: The total eleven randomized controlled trials (RCTs) involving 6,386 patients (pts) were included. 3,850 pts received ICC while 2536 pts received chemotherapy., Four studies each used atezolizumab and pembrolizumab while one study each used nivolumab, tislelizumab, and camrelizumab. The ICC group showed a significant improvement in both PFS (HR, 0.60; 95% CI, 0.54-0.66; p = < 0.00001) and OS (HR, 0.77; 95% CI, 0.68-0.87; p = < 0.0001). Atezolizumab combinations have better PFS and OS compared to the other combinations; HR 0.65 (0.59-0.71) and 0.82 (0.74-0.90), respectively. There was no statistically significant difference between the ICC and control groups regarding TRAEs (RR, 1.07; 95% CI, 0.99-1.16; p = 0.09). Further subgroup analysis is mentioned in the table. Conclusions: The ICC seems to be a promising front-line therapy for NSCLC with superior PFS and OS compared to chemotherapy alone and without significant increase in TRAES.
HR for PFS* | 0.60 (0.54-0.66) |
---|---|
Subgroup Analysis | |
Pembrolizumab* | 0.49 (0.38-0.61) |
Atezolizumab* | 0.65 (0.59-0.71) |
PD-L1 < 50%* | 0.64 (0.55-0.74) |
PDL1 ≥50%* | 0.40 (0.32-0.50) |
HR for OS* | 0.77 (0.68-0.87) |
Subgroup Analysis | |
Pembrolizumab* Atezolizumab* PD-L1 < 50% PDL1 ≥50%* | 0.76 (0.55-1.06) 0.83 (0.74-0.90) 0.78 (0.58-1.05) 0.64 (0.52-0.79) |
RR for TRAEs | 1.07 (0.99-1.16) |
* p = < 0.00001
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2023 ASCO Annual Meeting
First Author: Enrique Grande
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Lin Shen
2022 ASCO Annual Meeting
First Author: Luis G. Paz-Ares